Article
Cross-Species Hepatic Metabolism of the Antileishmanial Chalcone NAT22 Generates Metabolites with Enhanced Affinity for the Parasite Target cTXNPx
2026-03-03
Abstract excerpt
<h4>Background: </h4> /Objectives: Human and canine leishmaniasis are neglected diseases with limited therapeutic options. The nitrochalcone NAT22, a high-affinity inhibitor of the essential parasite enzyme tryparedoxin peroxidase (cTXNPx), has emerged as a promising antileishmanial candidate. Interestingly, NAT22 demonstrated superior efficacy when administered orally rather than intralesionally, suggesting metab...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- dd1856ef-df73-5aa0-9852-4a653639efec
- DOI
- 10.20944/preprints202603.0166.v1
